{"id":1066,"date":"2026-03-07T23:27:12","date_gmt":"2026-03-07T23:27:12","guid":{"rendered":"http:\/\/eurosoi.org\/?p=1066"},"modified":"2026-03-07T23:27:12","modified_gmt":"2026-03-07T23:27:12","slug":"after-48-hours-the-cells-were-washed-and-replated-with-rpmi-containing-the-same-concentration-of-gm-csf-and-il-4-for-another-5-days","status":"publish","type":"post","link":"https:\/\/eurosoi.org\/?p=1066","title":{"rendered":"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days"},"content":{"rendered":"<p>\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days. protein DAP12 and intracellular kinases Syk and PLC1. Pretreatment of mDC with the Syk inhibitor Piceatannol clogged B7-DC XAb-induced antigen uptake having a concomitant loss of tumor safety in mice. Vaccination with tumor <a href=\"http:\/\/www.dalida-show.com\/\">Rabbit Polyclonal to ERCC1<\/a> lysate-pulsed wildtype mDCXAb, but not TREM-2 knockout mDCXAb, safeguarded mice <a href=\"https:\/\/www.adooq.com\/pirenzepine-dihydrochloride.html\">Pirenzepine dihydrochloride<\/a> from lethal melanoma challenge. Multi-molecular caps Pirenzepine dihydrochloride appeared within minutes of B7-DC XAb binding to either human being or mouse mDC, and FRET analysis showed that class II, CD80, CD86 and TREM-2 are recruited in limited association within the cell surface. When TREM-2 manifestation was reduced in WT mDC using shRNA or by using mDC from TREM-2 knockout mice, in vitro DC failed to take up antigen after B7-DC XAb activation. These results directly link TREM-2 signaling with one switch in the mDC phenotype that occurs in response to this unique antibody. The parallel signaling events observed in both human being and mouse mDC support the hypothesis that B7-DC cross-linking may be useful like a restorative immune modulator in human being individuals. Keywords:Dendritic cells, antibodies, cell surface molecules, transmission transduction, antigen demonstration\/processing == Intro == Dendritic cells (DC) are key targets in techniques to regulate immunity for the treatment of malignancy, allergy, infectious diseases, transplant rejection, and autoimmunity (1). Activation of DC through the TLR family initiates DC maturation resulting in down rules of antigen uptake and migration to regional lymph nodes, where they encounter and activate nave T cells (2,3). As DC adult, the cell surface expression of a series of co-stimulatory molecules is definitely up controlled (4,5). These co-stimulatory molecules are critical for the activation of nave T cells (6). The triggered DC also create immunomodulating cytokines which influence the polarity of the ensuing immune response, determining the array of effector mechanisms brought to carry at the site of illness (7,8). We have recently described a new approach for modulating the activity of DC that is unique from previously defined mechanisms, yet results in potent immunomodulatory signals. B7-DC (or, PD-L2) is definitely a B7 family member normally expressed within the cell surface of dendritic cells (9). The receptor for this protein, PD-1, is indicated on triggered T cells (10). Cross-linking B7-DC in vitro or in vivo with the human being IgM antibody B7-DC XAb alters a wide variety of important functions of mDC, inducing 1) enhanced survival, 2) improved ability to process and present soluble antigen in the class I antigen-presenting pathway, 3) enhanced ability to activate nave T cells, 4) improved effectiveness of seeding draining lymph nodes, and 5) up-regulation of the key immunomodulating cytokine, IL-12 (11,12). However, mDC treated with B7-DC XAb do not display traditionally defined maturation phenotypes (12) such as an up-regulation of the co-stimulatory markers CD80 or CD86 or a concomitant increase in cell surface expression of class II antigen showing molecules. Instead, treatment of immature mDC with B7-DC XAb results in improved antigen uptake and even restores the ability of TLR-ligand matured mDC to take up and retain antigen (13). The combination of TLR-9 ligand and B7-DC cross-linking results in a synergistic CTL response against peptide antigen (13). These variations in maturation lead to important biological distinctions between cells triggered by traditional methods compared to cells triggered by cross-linking B7-DC. For example, mDC triggered with B7-DC XAb are highly efficient modulators of the polarity of Th2 memory space cells (14), efficiently redirect T regulatory cells into effector cell phenotypes (15), and rapidly activate cytolytic T cell reactions (16) whereas DC matured using TLR agonists are relatively inefficient inducers of these changes in T cell behavior. B7-DC connection with PD-1 offers been shown to result in either a positive response (9) or a negative response (10) by T cells. Pirenzepine dihydrochloride This discrepancy could be due either to the different model systems used or to the ability of B7-DC to interact with more than one of the receptors that differentially govern T Pirenzepine dihydrochloride cell responsiveness (17). The positive immune response observed when we treated animals with B7-DC XAb might also be attributable to a blockade of relationships between B7-DC and PD-1. However, adoptive transfer experiments using mDC triggered in vitro under conditions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days. protein DAP12 and intracellular kinases Syk and PLC1. Pretreatment of mDC with the Syk inhibitor Piceatannol clogged B7-DC XAb-induced antigen uptake having a concomitant loss of tumor <a href=\"https:\/\/eurosoi.org\/?p=1066\" class=\"btn btn-link continue-link\">Continue Reading<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69],"tags":[],"class_list":["post-1066","post","type-post","status-publish","format-standard","hentry","category-lipg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days - JAK2 inhibitor against human prostate cancer cells<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eurosoi.org\/?p=1066\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days - JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"og:description\" content=\"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days. protein DAP12 and intracellular kinases Syk and PLC1. Pretreatment of mDC with the Syk inhibitor Piceatannol clogged B7-DC XAb-induced antigen uptake having a concomitant loss of tumor Continue Reading\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eurosoi.org\/?p=1066\" \/>\n<meta property=\"og:site_name\" content=\"JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-07T23:27:12+00:00\" \/>\n<meta name=\"author\" content=\"info\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"info\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=1066#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=1066\"},\"author\":{\"name\":\"info\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"headline\":\"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days\",\"datePublished\":\"2026-03-07T23:27:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=1066\"},\"wordCount\":726,\"articleSection\":[\"LIPG\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=1066\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/?p=1066\",\"name\":\"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days - JAK2 inhibitor against human prostate cancer cells\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\"},\"datePublished\":\"2026-03-07T23:27:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=1066#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eurosoi.org\\\/?p=1066\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=1066#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eurosoi.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/\",\"name\":\"JAK2 inhibitor against human prostate cancer cells\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eurosoi.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\",\"name\":\"info\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"caption\":\"info\"},\"sameAs\":[\"http:\\\/\\\/eurosoi.org\"],\"url\":\"https:\\\/\\\/eurosoi.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days - JAK2 inhibitor against human prostate cancer cells","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eurosoi.org\/?p=1066","og_locale":"en_US","og_type":"article","og_title":"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days - JAK2 inhibitor against human prostate cancer cells","og_description":"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days. protein DAP12 and intracellular kinases Syk and PLC1. Pretreatment of mDC with the Syk inhibitor Piceatannol clogged B7-DC XAb-induced antigen uptake having a concomitant loss of tumor Continue Reading","og_url":"https:\/\/eurosoi.org\/?p=1066","og_site_name":"JAK2 inhibitor against human prostate cancer cells","article_published_time":"2026-03-07T23:27:12+00:00","author":"info","twitter_card":"summary_large_image","twitter_misc":{"Written by":"info","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eurosoi.org\/?p=1066#article","isPartOf":{"@id":"https:\/\/eurosoi.org\/?p=1066"},"author":{"name":"info","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"headline":"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days","datePublished":"2026-03-07T23:27:12+00:00","mainEntityOfPage":{"@id":"https:\/\/eurosoi.org\/?p=1066"},"wordCount":726,"articleSection":["LIPG"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/eurosoi.org\/?p=1066","url":"https:\/\/eurosoi.org\/?p=1066","name":"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days - JAK2 inhibitor against human prostate cancer cells","isPartOf":{"@id":"https:\/\/eurosoi.org\/#website"},"datePublished":"2026-03-07T23:27:12+00:00","author":{"@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"breadcrumb":{"@id":"https:\/\/eurosoi.org\/?p=1066#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eurosoi.org\/?p=1066"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eurosoi.org\/?p=1066#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eurosoi.org\/"},{"@type":"ListItem","position":2,"name":"\ufeffAfter 48 hours, the cells were washed and replated with RPMI containing the same concentration of GM-CSF and IL-4 for another 5 days"}]},{"@type":"WebSite","@id":"https:\/\/eurosoi.org\/#website","url":"https:\/\/eurosoi.org\/","name":"JAK2 inhibitor against human prostate cancer cells","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eurosoi.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd","name":"info","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","caption":"info"},"sameAs":["http:\/\/eurosoi.org"],"url":"https:\/\/eurosoi.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/1066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1066"}],"version-history":[{"count":1,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/1066\/revisions"}],"predecessor-version":[{"id":1067,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/1066\/revisions\/1067"}],"wp:attachment":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}